Please login to the form below

Not currently logged in
Email:
Password:

Sanofi enters deal with Scripps

Sanofi-aventis(S-A) has entered into a partnership with Scripps Genomic Medicine

Sanofi-aventis(S-A) has entered into a partnership with Scripps Genomic Medicine, a research division of the $2.2bn not-for-profit San Diego-based community health system.

The alliance will focus on research and development initiatives in personalised medicine. The deal calls for sanofi-aventis Recherche & Developpement, a subsidiary of sanofi-aventis Group, to provide up to three grants a year as a form of flexible financing for research by Scripps investigators. In exchange, sanofi-aventis will gain non-exclusive rights to research tools developed through the grants, as well as preferred access to Scripps laboratory facilities for work conducted in support of sponsored research agreements and discoveries in personalised medicine. 

The two companies will also organise an annual research symposium intended to give sanofi-aventis access to Scripps research programmes that can contribute to the company's priority areas.

Scripps Genomic Medicine is genotyping and storing genetic data on thousands of diverse volunteers culled from the 500,000 patients that the health system treats each year. The information is intended to be used in drug discovery programmes and gene-specific clinical trials that target groups of 500 subjects or less who share a particular gene variant. The targeted trials are expected to shorten drug development time and to lead to therapies that are safer and more effective for particular subgroups of patients.

10th August 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics